Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chimeric kinase ALK induces expression of NAMPT and selectively depends on this metabolic enzyme to sustain its own oncogenic function.
Zhang Q, Basappa J, Wang HY, Nunez-Cruz S, Lobello C, Wang S, Liu X, Chekol S, Guo L, Ziober A, Nejati R, Shestov A, Feldman M, Glickson JD, Turner SD, Blair IA, Van Dang C, Wasik MA. Zhang Q, et al. Among authors: nejati r. Leukemia. 2023 Dec;37(12):2436-2447. doi: 10.1038/s41375-023-02038-0. Epub 2023 Sep 29. Leukemia. 2023. PMID: 37773266
IGH/MYC Translocation Associates with BRCA2 Deficiency and Synthetic Lethality to PARP1 Inhibitors.
Maifrede S, Martin K, Podszywalow-Bartnicka P, Sullivan-Reed K, Langer SK, Nejati R, Dasgupta Y, Hulse M, Gritsyuk D, Nieborowska-Skorska M, Lupey-Green LN, Zhao H, Piwocka K, Wasik MA, Tempera I, Skorski T. Maifrede S, et al. Among authors: nejati r. Mol Cancer Res. 2017 Aug;15(8):967-972. doi: 10.1158/1541-7786.MCR-16-0468. Epub 2017 Jun 20. Mol Cancer Res. 2017. PMID: 28634224 Free PMC article.
TGFβR-SMAD3 Signaling Induces Resistance to PARP Inhibitors in the Bone Marrow Microenvironment.
Le BV, Podszywalow-Bartnicka P, Maifrede S, Sullivan-Reed K, Nieborowska-Skorska M, Golovine K, Yao JC, Nejati R, Cai KQ, Caruso LB, Swatler J, Dabrowski M, Lian Z, Valent P, Paietta EM, Levine RL, Fernandez HF, Tallman MS, Litzow MR, Huang J, Challen GA, Link D, Tempera I, Wasik MA, Piwocka K, Skorski T. Le BV, et al. Among authors: nejati r. Cell Rep. 2020 Oct 6;33(1):108221. doi: 10.1016/j.celrep.2020.108221. Cell Rep. 2020. PMID: 33027668 Free PMC article.
Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication.
Lu P, Wang S, Franzen CA, Venkataraman G, McClure R, Li L, Wu W, Niu N, Sukhanova M, Pei J, Baldwin DA, Nejati R, Wasik MA, Khan N, Tu Y, Gao J, Chen Y, Ma S, Larson RA, Wang YL. Lu P, et al. Among authors: nejati r. Blood Cancer J. 2021 Feb 18;11(2):39. doi: 10.1038/s41408-021-00429-z. Blood Cancer J. 2021. PMID: 33602908 Free PMC article.
Induction of Transcriptional Inhibitor HES1 and the Related Repression of Tumor-Suppressor TXNIP Are Important Components of Cell-Transformation Program Imposed by Oncogenic Kinase NPM-ALK.
Zhang Q, Wang HY, Nayak A, Nunez-Cruz S, Slupianek A, Liu X, Basappa J, Fan JS, Chekol S, Nejati R, Bogusz AM, Turner SD, Swaminathan K, Wasik MA. Zhang Q, et al. Among authors: nejati r. Am J Pathol. 2022 Aug;192(8):1186-1198. doi: 10.1016/j.ajpath.2022.05.005. Epub 2022 May 28. Am J Pathol. 2022. PMID: 35640677 Free PMC article.
Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop.
Czader M, Amador C, Cook JR, Thakkar D, Parker C, Dave SS, Dogan A, Duffield AS, Nejati R, Ott G, Xiao W, Wasik M, Goodlad JR. Czader M, et al. Among authors: nejati r. Am J Clin Pathol. 2023 Jun 1;159(6):554-571. doi: 10.1093/ajcp/aqad027. Am J Clin Pathol. 2023. PMID: 37052539 Free PMC article.
46 results